You are here:
| Reference : In vitro and in vivo activity of the nuclear factor-kappa B inhibitor sulfasalazine in h... |
| Scientific journals : Article | |||
| Human health sciences : Neurology | |||
| http://hdl.handle.net/2268/61896 | |||
| In vitro and in vivo activity of the nuclear factor-kappa B inhibitor sulfasalazine in human glioblastomas. | |
| English | |
| Robe, Pierre [Centre Hospitalier Universitaire de Liège - CHU > > Neurochirurgie >] | |
| Bentires-Alj, Mohamed [Centre Hospitalier Universitaire de Liège - CHU > Center for Cellular and Molecular Therapeutics > > >] | |
| Bonif, Marianne [Centre Hospitalier Universitaire de Liège - CHU > Center for Cellular and Molecular Therapeutics > > >] | |
| Rogister, Bernard [Centre Hospitalier Universitaire de Liège - CHU > > Neurologie Sart Tilman >] | |
Deprez, Manuel  [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques >] | |
| Haddada, Heddi [Institut Gustave-Roussy, Villejuif, France > Unite´ INSERM 487 > > >] | |
| Khac, Minh-Tuan Nguyen [Centre Hospitalier Universitaire de Liège - CHU > Center for Cellular and Molecular Therapeutics > > >] | |
| Jolois, Olivier [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Histologie humaine >] | |
| Erkmen, Kadir [Children’s Hospital, Harvard Medical School, Boston > Department of Neurosurgery > > >] | |
| Merville, Marie-Paule [Université de Liège - ULg > Département de pharmacie > Chimie médicale >] | |
| Black, Peter M [Children’s Hospital, Harvard Medical School, Boston > Department of Neurosurgery > > >] | |
| Bours, Vincent [Centre Hospitalier Universitaire de Liège - CHU > > Génétique >] | |
| 2004 | |
| Clinical Cancer Research : An Official Journal of the American Association for Cancer Research | |
| American Association for Cancer Research, Inc. (AACR) | |
| 10 | |
| 16 | |
| 5595-603 | |
| Yes (verified by ORBi) | |
| International | |
| 1078-0432 | |
| Birmingham | |
| AL | |
| [en] Anti-Inflammatory Agents, Non-Steroidal/toxicity ; Antineoplastic Agents ; Brain Neoplasms/drug therapy/pathology ; Cell Line, Tumor ; Gene Therapy ; Glioblastoma/drug therapy/pathology ; Humans ; NF-kappa B/antagonists & inhibitors ; Sulfasalazine/toxicity ; Tumor Cells, Cultured | |
| [en] Glioblastomas, the most common primary brain cancers, respond poorly to current treatment modalities and carry a dismal prognosis. In this study, we demonstrated that the transcription factor nuclear factor (NF)-kappaB is constitutively activated in glioblastoma surgical samples, primary cultures, and cell lines and promotes their growth and survival. Sulfasalazine, an anti-inflammatory drug that specifically inhibits the activation of NF-kappaB, blocked the cell cycle and induced apoptosis in several glioblastoma cell lines and primary cultures, as did gene therapy with a vector encoding a super-repressor of NF-kappaB. In vivo, sulfasalazine also significantly inhibited the growth of experimental human glioblastomas in nude mice brains. Given the documented safety of sulfasalazine in humans, these results may lead the way to a new class of glioma treatment. | |
| Researchers ; Professionals | |
| http://hdl.handle.net/2268/61896 | |
| 10.1158/1078-0432.CCR-03-0392 | |
| Must link to the publisher PDF of article on journal website http://www.aacr.org/ subject to Restrictions below, author can archive post-print (ie final draft post-refereeing)
Restrictions: * 12 months embargo |
| File(s) associated to this reference | ||||||||||||||
|
Fulltext file(s):
| ||||||||||||||
All documents in ORBi are protected by a user license.
